SNCA and Parkinson disease: Similar to SNCA, LRRK2 is another substrate of CMA, but the LRRK2G2019S mutant is again difficult to degrade and inhibits CMA, which underlies the toxicity in PD by compromising the CMA-mediated degradation of SNCA [197,198].